Conduit Pharmaceuticals Inc. (NASDAQ:CDT - Get Free Report) Director Andrew Regan sold 35,923 shares of Conduit Pharmaceuticals stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $0.51, for a total transaction of $18,320.73. Following the completion of the sale, the director now owns 15,441,772 shares of the company's stock, valued at $7,875,303.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Andrew Regan also recently made the following trade(s):
- On Wednesday, July 17th, Andrew Regan sold 1,514,100 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.26, for a total value of $393,666.00.
- On Monday, July 15th, Andrew Regan sold 1,005,200 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.25, for a total transaction of $251,300.00.
- On Friday, July 12th, Andrew Regan sold 1,389,820 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.25, for a total transaction of $347,455.00.
- On Wednesday, July 10th, Andrew Regan sold 150,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.33, for a total transaction of $49,500.00.
- On Wednesday, July 3rd, Andrew Regan sold 1,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.64, for a total value of $640.00.
Conduit Pharmaceuticals Price Performance
Biden's Executive Order, Dems Digital Money Legislation, First Step To
From Monetary Gold | Ad
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs).
If these plans are implemented, it could mean the end of America as we know it.
This means you must act NOW before it's too late.
NASDAQ CDT opened at $0.13 on Friday. The company has a fifty day simple moving average of $0.18 and a two-hundred day simple moving average of $1.78. Conduit Pharmaceuticals Inc. has a 12-month low of $0.11 and a 12-month high of $22.00.
Conduit Pharmaceuticals (NASDAQ:CDT - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.07) EPS for the quarter.
Analyst Upgrades and Downgrades
Separately, Berenberg Bank raised shares of Conduit Pharmaceuticals to a "strong-buy" rating in a research report on Friday, July 26th.
Get Our Latest Research Report on CDT
Conduit Pharmaceuticals Company Profile
(
Get Free Report)
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
